Reverse transcriptase · SINGLE PROTEIN · Human immunodeficiency virus 2
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Reverse transcriptase shows late clinical disease relevance led by HIV infection. 4 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q06347. Start with HIV infection, then reuse UniProt Q06347 as the stable protein anchor across project notes and exports.
Start with HIV infection, then reuse UniProt Q06347 as the stable protein anchor across project notes and exports.
Reverse transcriptase shows late clinical disease relevance led by HIV infection. 4 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with HIV infection because it currently carries late clinical support. Linked drugs include APRICITABINE, ISLATRAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyReverse transcriptase
Review this target as Reverse transcriptase, mapped to UniProt Q06347. Sequence length is 560 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Reverse transcriptase as ChEMBL target CHEMBL1681630, mapped to UniProt Q06347. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Reverse transcriptase is the right protein anchor across sources, using UniProt Q06347 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why HIV infection is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Reverse transcriptase |
| Target Type | SINGLE PROTEIN |
| Organism | Human immunodeficiency virus 2 |
| UniProt | Q06347 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Reverse transcriptase |
| UniProt Accession | Q06347 |
| Component Type | Protein |
| Sequence Length | 560 aa |
Reverse transcriptase
Review this target as Reverse transcriptase, mapped to UniProt Q06347. Sequence length is 560 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Reverse transcriptase shows late clinical disease relevance led by HIV infection. 4 more disease programs remain visible in the same review block.
Start review with HIV infection because it currently carries late clinical support. Linked drugs include APRICITABINE, ISLATRAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL550937 | 6.6 | IC50 | 250.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 3 | 1 | 6.6 |